Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Axces Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$1,147,216

180 payments

Through program year 2025, Axces Research Group LLC is reported as receiving $1,147,216 in research payments, across 180 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $680,719 136
2024 Research $97,224 17
2023 Research $214,396 8
2022 Research $7,931 3
2021 Research $134,945 15
2020 Research $12,000 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. ViiV Healthcare Company $651,976 119 payments
  2. Novavax Inc $115,722 19 payments
  3. Quidel Corporation $115,000 2 payments
  4. Gilead Sciences, Inc. $88,889 10 payments
  5. Moderna TX, Inc. $69,986 18 payments
  6. Pfizer Inc. $65,987 9 payments
  7. Cue Health Inc. $31,492 1 payment
  8. Currax Pharmaceuticals LLC $8,164 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff $651,976 119 payments
  2. CS-0172-01: QuickVue ABC Validation Study $115,000 2 payments
  3. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $69,986 18 payments
  4. A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naive Participants $67,904 5 payments
  5. An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $47,952 7 payments
  6. A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve Participants $47,818 14 payments
  7. Cp-Ctng $31,492 1 payment
  8. A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $18,035 2 payments
  9. A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS 5423 and GS 2872 in Combination with Capsid Inhibitor Lenacapavir (GS 6207) in Virologically Suppressed Adults with HIV-1 Infection $17,500 1 payment
  10. A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV $15,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record